By CGT Global
Updated October 14, 2025
CGT Global has published its full Clinical Commercial Solutions Guide and launched their new Clinical Donor Screening services. Now, researchers and therapeutic developers can discover how CGT Global is utilizing a nationwide & coast-to-coast footprint of privately owned and operated collection facilities to support the cell and gene therapy market with GMP-compliant leukapheresis and more.
As more cellular therapy candidates move through IND into Phase I and beyond, there is a growing need for Clinical ready partners to supply critical starting material from healthy donors and patients. CGT Global provides GMP-compliant leukopaks to supply all phases of clinical trial advancement as well as commercialization. GMP Leukopaks are available from all six (3) of their collection facilities in strategic locations for seamless logistics to major cell therapy manufacturing hubs.
For allogeneic therapies, CGT Global knows that a rigorous process of screening and process testing to pre-approve donors for a clinical manufacturing run is often required. Clinical Donor Screening is a new and unique service among cellular starting material providers and CGT Global is proud to support the screening, selection, and maintenance of client-specific or program-specific vetted and qualified donors utilizing their full donor pool network and facilities operating under a single Quality Management System.
To request a digital PDF copy of the Clinical Commercial Guide visit: https://cgt.global/clinical-capabilities/
About CGT Global:
Headquartered in Folsom, California, CGT Global is a leading global provider of human primary cells, stem cells, bone marrow, cord blood, peripheral blood, and disease-state products. Their products are used for research and development, clinical trials, and commercial production of cell and gene therapies (allogeneic or autologous) by academic, biotech, diagnostic, pharmaceutical and contract research organizations (CRO’s).
CGT Global is registered with the U.S. Food and Drug Administration (FDA) and has over a dozen global distribution partners and six (3) privately owned locations in the United States. It has been ranked by Inc. 500 as one of the fastest growing companies in the U.S. Learn more at StemExpress.com.”
